Weinstein G D, Nigra T P, Pochi P E, Savin R C, Allan A, Benik K, Jeffes E, Lufrano L, Thorne E G
Department of Dermatology, University of California, Irvine 92717.
Arch Dermatol. 1991 May;127(5):659-65.
The clinical and histologic effects of a new emollient cream formulation of topical tretinoin at concentrations of 0.05% and 0.01% were examined in 251 subjects with mild to moderate photodamaged facial skin in a randomized, double-blind, vehicle-controlled, multicenter study. Seventy-nine percent of the subjects who received 0.05% tretinoin for 24 weeks showed overall improvement in photodamaged skin compared with improvement in 48% of the vehicle-treated control subjects. Significant reductions were found in fine wrinkling, mottled hyperpigmentation, roughness, and laxity after 0.05% tretinoin therapy when compared with controls. In addition, histologic changes of increased epidermal thickness, decreased melanin content, and stratum corneum compaction provide independent evidence supporting clinical improvement. Side effects of erythema, peeling, and stinging were usually mild and well tolerated.
在一项随机、双盲、赋形剂对照、多中心研究中,对251名面部皮肤有轻度至中度光损伤的受试者,研究了浓度为0.05%和0.01%的新型外用维甲酸润肤霜配方的临床和组织学效果。接受0.05%维甲酸治疗24周的受试者中,79%的光损伤皮肤有整体改善,相比之下,赋形剂治疗的对照受试者中这一比例为48%。与对照组相比,0.05%维甲酸治疗后,细纹、斑驳色素沉着、粗糙度和皮肤松弛度均有显著降低。此外,表皮增厚、黑色素含量降低和角质层致密化的组织学变化为临床改善提供了独立证据。红斑、脱皮和刺痛等副作用通常较轻,耐受性良好。